Silencing of the GnRH type 1 receptor blocks the antiproliferative effect of the GnRH agonist, leuprolide, on the androgen-independent prostate cancer cell line DU145

Journal of International Medical Research

Volumn 39, Issue 3, 2011, Pages 729-739

  Ko, Y H ^a   Ha, Y R ^a   Kim, J W ^a   Kang, S G ^a   Jang, H A ^a   Kang, S H ^a   Park, H S ^a   Cheon, J ^a  

^a Korea University College of Medicine   (South Korea)

Author keywords

Cell proliferation; DU145 cells; GnRH type 1 receptor; Gonadotropin releasing hormone (GnRH) agonist; Hormone therapy; Leuprolide; Prostate cancer

Indexed keywords

GONADORELIN RECEPTOR; GONADORELIN RECEPTOR 1; LEUPRORELIN; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG;

ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER INHIBITION; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG MECHANISM; GENE; GENE EXPRESSION; GENE SILENCING; GENETIC TRANSFECTION; GNRHR1 GENE; PROSTATE CANCER; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

EID: 80052197646     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/147323001103900304     Document Type: Article

References (30)

1. Conn PM, Crowley WF: Gonadotropin-releasing hormone and its analogs. Annu Rev Med 1994; 45: 391-405.
2. Belchetz PE, Plant TM, Nakai Y, et al: Hypophysial responses to continuous and intermittent delivery of hypopthalamic gonadotropin-releasing hormone. Science 1978; 202: 631-633.
3. Angelucci C, Lama G, Iacopino F, et al: GnRH receptor expression in human prostate cancer cells is affected by hormones and growth factors. Endocrine 2009; 36: 87-97.
4. Limonta P, Dondi D, Moretti RM, et al: Antiproliferative effects of luteinizing hormonereleasing hormone agonists on the human prostatic cancer cell line LNCaP. J Clin Endocrinol Metab 1992; 75: 207-212.
5. Straub B, Müller M, Krause H, et al: Increased incidence of luteinizing hormone-releasing hormone receptor gene messenger RNA expression in hormone-refractory human prostate cancers. Clin Cancer Res 2001; 7: 2340-2343.
6. Armstrong SP, Caunt CJ, Fowkes RC, et al: Pulsatile and sustained gonadotropin-releasing hormone (GnRH) receptor signaling. J Biol Chem 2009; 284: 35746-35757.
7. Millar RP, Pawson AJ: Outside-in and inside-out signaling: the new concept that selectivity of ligand binding at the gonadotropin-releasing hormone receptor is modulated by the intracellular environment. Endocrinology 2004; 145: 3590-3593.
8. Fire A, Xu S, Montgomery MK, et al: Potent and specific genetic interference by double-stranded RNA in Caernohabditis elegans. Nature 1998; 391: 806-811.
9. Limonta P, Montagnani Marelli M, Moretti RM: LHRH analogues as anticancer agents: pituitary and extrapituitary sites of action. Expert Opin Investig Drugs 2001; 10: 709-720.
10. Dondi D, Limonta P, Moretti RM, et al: Antiproliferative effects of luteinizing hormonereleasing hormone (LHRH) agonists on human androgen-independent prostate cancer cell line DU145: evidence for an autocrine-inhibitory LHRH loop. Cancer Res 1994; 54: 4091-4095.
11. Limonta P, Dondi D, Moretti RM, et al: Expression of luteinizing hormone-releasing hormone mRNA in the human prostatic cancer cell line LNCaP. J Clin Endocrinol Metab 1993; 76: 797-800.
12. Qayum A, Gullick W, Clayton RC, et al: The effects of gonadotrophin releasing hormone analogues in prostate cancer are mediated through specific tumour receptors. Br J Cancer 1990; 62: 96-99.
13. Bahk JY, Hyun JS, Lee H, et al: Expression of gonadotropin-releasing hormone (GnRH) and GnRH receptor mRNA in prostate cancer cells and effect of GnRH on the proliferation of prostate cancer cells. Urol Res 1998; 26: 259-264.
14. Ravenna L, Salvatori L, Morrone S, et al: Effects of triptorelin, a gonadotropin-releasing hormone agonist, on the human prostatic cell lines PC3 and LNCaP. J Androl 2000; 21: 549-557.
15. Cheng CK, Leung PC: Molecular biology of gonadotropin-releasing hormone (GnRH)-I, GnRH-II, and their receptors in humans. Endocr Rev 2005; 26: 283-306.
16. Maudsley S, Davidson L, Pawson AJ, et al: Gonadotropin-releasing hormone (GnRH) antagonists promote proapoptotic signaling in peripheral reproductive tumor cells by activating a Galphai-coupling state of the type I GnRH receptor. Cancer Res 2004; 64: 7533-7544.
17. Choi KC, Auersperg N, Leung PC: Expression and antiproliferative effect of a second form of gonadotropin-releasing hormone in normal and neoplastic ovarian surface epithelial cells. J Clin Endocrinol Metab 2001; 86: 5075-5078.
18. Millar RP: GnRH II and type II GnRH receptors. Trends Endocrinol Metab 2003; 14: 35-43.
19. Montagnani Marelli M, Moretti RM, Mai S, et al: Type I gonadotropin-releasing hormone receptor mediates the antiproliferative effects of GnRH-II on prostate cancer cells. J Clin Endocrinol Metab 2009; 94: 1761-1767.
20. Tuschl T: Expanding small RNA interference. Nat Biotechnol 2002; 20: 446-448.
21. Brummelkamp TR, Bernards R, Agami R: Stable suppression of tumorigenicity by virusmediated RNA interference. Cancer Cell 2002; 2: 243-247.
22. Brummelkamp TR, Bernards R, Agami R: A system for stable expression of short interfering RNAs in mammalian cells. Science 2002; 296: 550-553.
23. Sharma R, Hamilton A, Beith J: LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women. Cochrane Database Syst Rev 2008; 4: CD004562.
24. Gründker C, Günthert AR, Westphalen S, et al: Biology of the gonadotropin-releasing hormone system in gynecological cancers. Eur J Endocrinol 2002; 146: 1-14.
25. Marelli MM, Moretti RM, Januszkiewicz-Caulier J, et al: Gonadotropin-releasing hormone (GnRH) receptors in tumors: a new rationale for the therapeutical application of GnRH analogs in cancer patients? Curr Cancer Drug Targets 2006; 6: 257-269.
26. Imai A, Takagi H, Horibe S, et al: Coupling of gonadotropin-releasing hormone receptor to Gi protein in human reproductive tract tumors. J Clin Endocrinol Metab 1996; 81: 3249-3253.
27. Hsieh KP, Martin TF: Thyrotropin-releasing hormone and gonadotropin-releasing hormone receptors activate phospholipase C by coupling to the guanosine triphosphate-binding proteins Gq and G11. Mol Endocrinol 1992; 6: 1673-1681.
28. Levi NL, Hanoch T, Benard O, et al: Stimulation of Jun N-terminal kinase (JNK) by gonadotropin-releasing hormone in pituitary αT3-1 cell line is mediated by protein kinase C, c-Src, and CDC42. Mol Endocrinol 1998; 12: 815-824.
29. Stojilkovic SS, Catt KJ: Expression and signal transduction pathways of gonadotropinreleasing hormone receptors. Recent Prog Horm Res 1995; 50: 161-205.
30. Enomoto M, Utsumi M, Park MK: Gonadotropin-releasing hormone induces actin cytoskeleton remodeling and affects cell migration in a cell-type-specific manner in TSU-Pr1 and DU145 cells. Endocrinology 2006; 147: 530-542.